Companies /Healthcare

Neoleukin Therapeutics Inc

NASDAQ: NGNE Biotechnology
$38.68
â–² $0.27 (+0.70%) today
Markets open · 3:49pm ET
Today · % change

Fundamentals

Market Cap
$768.6M
EPS (TTM)
$-4.73
52-Week Range
$16 – $44
Street Target
$80.43

About Neurogene

Neoleukin Therapeutics Inc, based in New York, focuses on creating genetic medicines to transform the lives of patients and families dealing with neurological diseases. Their innovative work includes NGN-401, a promising gene therapy aimed at combating Rett syndrome, and NGN-101, designed to tackle neuronal ceroid lipofuscinosis subtype 5 batten disease. Their dedication to addressing these challenging conditions highlights their commitment to advancing medical science and improving patient care.

NGNE Coverage